Selumetinib with and without erlotinib in KRAS mutant and KRAS wild-type advanced nonsmall-cell lung cancer

摘要

This study failed to show improvement of combination therapy using an epidermal growth factor receptor tyrosine kinase inhibitor combined with an MEK inhibitor over single-agent therapy in KRAS wild-type and mutant patients. Toxicity was significantly increased when the two drugs are combined.KRAS mutations in NSCLC are associated with a lack of response to epidermal growth factor receptor inhibitors. Selumetinib (AZD6244; ARRY-142886) is an oral selective MEK kinase inhibitor of the Ras/Raf/MEK/ERK pathway.